{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Mellein (3,4-dihydroisocoumarin) is a dihydroisocoumarin, a phenolic compound produced by Aspergillus ochraceus, with potent anti-hepatitis C virus protease activity. Mellein is a common metabolite in fungi and molds and particularly in endophytic fungi associated with higher plants. Occasionally, it has been isolated from some higher plants such as Ficus formosana (Moraceae) and Garcinia bancana (Clusiaceae) and also from marine organisms. On the other hand, it is particularly notable the presence of this compound in insects in which acts as a pheromone and as a defense substance. Mellein has been recognized for its antibacterial, phytotoxic, larvicide and fungicide activities, and also because it acts as an inhibitor of HCV protease enzyme and prostaglandin synthesis.
Status:
First approved in 1960
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatment of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism.
Status:
US Approved OTC
Source:
21 CFR 341.12(b) cough/cold:antihistamine chlorcyclizine hydrochloride
Source URL:
First approved in 1949
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms. Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic. Chlorcyclizine temporarily relieves the symptoms due to hay fever or other upper respiratory allergies. It has also being shown to possess in vitro and in vivo activity against hepatitis C virus.
Status:
US Approved OTC
Source:
21 CFR 341.12(b) cough/cold:antihistamine chlorcyclizine hydrochloride
Source URL:
First approved in 1949
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms. Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic. Chlorcyclizine temporarily relieves the symptoms due to hay fever or other upper respiratory allergies. It has also being shown to possess in vitro and in vivo activity against hepatitis C virus.
Status:
US Approved OTC
Source:
21 CFR 341.12(b) cough/cold:antihistamine chlorcyclizine hydrochloride
Source URL:
First approved in 1949
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Chlorcyclizine is a first generation phenylpiperazine class antihistamine used to treat urticaria, rhinitis, pruritus, and other allergy symptoms. Chlorcyclizine also has some local anesthetic, anticholinergic, and antiserotonergic properties, and can be used as an antiemetic. Chlorcyclizine temporarily relieves the symptoms due to hay fever or other upper respiratory allergies. It has also being shown to possess in vitro and in vivo activity against hepatitis C virus.
Status:
Investigational
Source:
NCT03505684: Not Applicable Interventional Completed Skin Manifestations
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT03505684: Not Applicable Interventional Completed Skin Manifestations
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT03505684: Not Applicable Interventional Completed Skin Manifestations
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
First approved in 1960
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatment of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism.